Diabetic Retinopathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Diabetic Retinopathy – Pipeline Review, H2 2016’, provides an overview of the Diabetic Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acucela Inc.

Aerie Pharmaceuticals, Inc.

Aerpio Therapeutics, Inc.

Amakem NV

Antisense Therapeutics Limited

Araim Pharmaceuticals, Inc.

BCN Peptides, S.A.

Biomar Microbial Technologies

Charlesson LLC.

Coherus BioSciences, Inc.

Crinetics Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics, Inc.

EyeGene Inc

Foresee Pharmaceuticals, LLC

Formycon AG

Icon Bioscience, Inc.

Islet Sciences, Inc.

Kodiak Sciences Inc.

Kowa Company, Ltd.

LegoChem Biosciences, Inc

Lpath, Inc.

M's Science Corporation

Mabion SA

MingSight Pharmaceuticals

OcuCure Therapeutics, Inc.

Oculis ehf

Ohr Pharmaceutical Inc.

PanOptica, Inc.

Profarma

Promedior, Inc.

Regeneron Pharmaceuticals Inc

Retrotope, Inc

Ribomic Inc.

Stelic Institute & Co., Inc.

Stemedica Cell Technologies, Inc.

Strongbridge Biopharma plc

Sucampo Pharmaceuticals, Inc.

Targazyme, Inc.

ThromboGenics NV

TWi Pharmaceuticals, Inc.

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Diabetic Retinopathy Overview 10

Therapeutics Development 11

Pipeline Products for Diabetic Retinopathy - Overview 11

Pipeline Products for Diabetic Retinopathy - Comparative Analysis 12

Diabetic Retinopathy - Therapeutics under Development by Companies 13

Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 17

Diabetic Retinopathy - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Diabetic Retinopathy - Products under Development by Companies 22

Diabetic Retinopathy - Products under Investigation by Universities/Institutes 26

Diabetic Retinopathy - Companies Involved in Therapeutics Development 27

Acucela Inc. 27

Aerie Pharmaceuticals, Inc. 28

Aerpio Therapeutics, Inc. 29

Amakem NV 30

Antisense Therapeutics Limited 31

Araim Pharmaceuticals, Inc. 32

BCN Peptides, S.A. 33

Biomar Microbial Technologies 34

Charlesson LLC. 35

Coherus BioSciences, Inc. 36

Crinetics Pharmaceuticals, Inc. 37

Diffusion Pharmaceuticals Inc 38

Dimerix Bioscience Pty Ltd 39

Dynamis Therapeutics, Inc. 40

EyeGene Inc 41

Foresee Pharmaceuticals, LLC 42

Formycon AG 43

Icon Bioscience, Inc. 44

Islet Sciences, Inc. 45

Kodiak Sciences Inc. 46

Kowa Company, Ltd. 47

LegoChem Biosciences, Inc 48

Lpath, Inc. 49

M's Science Corporation 50

Mabion SA 51

MingSight Pharmaceuticals 52

OcuCure Therapeutics, Inc. 53

Oculis ehf 54

Ohr Pharmaceutical Inc. 55

PanOptica, Inc. 56

Profarma 57

Promedior, Inc. 58

Regeneron Pharmaceuticals Inc 59

Retrotope, Inc 60

Ribomic Inc. 61

Stelic Institute & Co., Inc. 62

Stemedica Cell Technologies, Inc. 63

Strongbridge Biopharma plc 64

Sucampo Pharmaceuticals, Inc. 65

Targazyme, Inc. 66

ThromboGenics NV 67

TWi Pharmaceuticals, Inc. 68

VESSL Therapeutics Ltd 69

Diabetic Retinopathy - Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 76

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

(irbesartan + propagermanium) - Drug Profile 84

A-717 - Drug Profile 87

AC-301 - Drug Profile 88

aflibercept - Drug Profile 89

AKB-9778 - Drug Profile 100

ALG-1001 - Drug Profile 104

AMA-0428 - Drug Profile 107

APTA-1004 - Drug Profile 108

Aptamers for Diabetic Retinopathy - Drug Profile 109

AR-13154 - Drug Profile 110

atesidorsen sodium - Drug Profile 111

Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 119

BNN-27 - Drug Profile 120

cibinetide - Drug Profile 121

CLT-005 - Drug Profile 124

CLT-020 - Drug Profile 125

COR-005 - Drug Profile 126

cyclosporine - Drug Profile 129

Cyndacel-M - Drug Profile 130

DMX-400 - Drug Profile 131

Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 132

DT-23552 - Drug Profile 133

DYN-12 - Drug Profile 134

E-1086 - Drug Profile 135

EG-Mirotin - Drug Profile 136

emixustat hydrochloride - Drug Profile 137

FP-008 - Drug Profile 141

GLY-230 - Drug Profile 142

IB-09A0133 - Drug Profile 143

IVMED-60 - Drug Profile 144

JP-153 - Drug Profile 145

KSI-301 - Drug Profile 146

L-779976 - Drug Profile 147

LCB-030110 - Drug Profile 148

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 149

Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile 150

MS-553 - Drug Profile 151

MultiGeneEye - Drug Profile 152

Nextomabs - Drug Profile 153

NM-108 - Drug Profile 154

OC-10X - Drug Profile 155

OC-410 - Drug Profile 156

ocriplasmin - Drug Profile 157

OCU-200 - Drug Profile 163

OCX-063 - Drug Profile 164

OLX-302 - Drug Profile 165

PAN-90806 - Drug Profile 166

PF-07 - Drug Profile 168

PRM-167 - Drug Profile 169

Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 170

ranibizumab biosimilar - Drug Profile 171

ranibizumab biosimilar - Drug Profile 172

ranibizumab biosimilar - Drug Profile 174

RBM-008 - Drug Profile 175

Recombinant Protein for Oncology and Diabetic Retinopathy - Drug Profile 176

Recombinant Protein To Target Caspases for Diabetic Retinopathy, Macular Degeneration and Solid Tumor - Drug Profile 177

RES-529 - Drug Profile 178

ripasudil - Drug Profile 182

RT-001 - Drug Profile 184

RT-002 - Drug Profile 186

RTU-1096 - Drug Profile 187

somatostatin - Drug Profile 188

squalamine lactate - Drug Profile 189

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 197

Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 203

STNM-1510 - Drug Profile 204

Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile 205

THR-687 - Drug Profile 206

TZ-101 - Drug Profile 207

V-1932 - Drug Profile 210

Wnt-001 - Drug Profile 211

Diabetic Retinopathy - Dormant Projects 212

Diabetic Retinopathy - Discontinued Products 218

Diabetic Retinopathy - Product Development Milestones 219

Featured News & Press Releases 219

Appendix 231

Methodology 231

Coverage 231

Secondary Research 231

Primary Research 231

Expert Panel Validation 231

Contact Us 231

Disclaimer 232

List of Tables

List of Tables

Number of Products under Development for Diabetic Retinopathy, H2 2016 16

Number of Products under Development for Diabetic Retinopathy – Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Development by Companies, H2 2016 (Contd..1) 19

Number of Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Development by Companies, H2 2016 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2016 31

Diabetic Retinopathy – Pipeline by Acucela Inc., H2 2016 32

Diabetic Retinopathy – Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 33

Diabetic Retinopathy – Pipeline by Aerpio Therapeutics, Inc., H2 2016 34

Diabetic Retinopathy – Pipeline by Amakem NV, H2 2016 35

Diabetic Retinopathy – Pipeline by Antisense Therapeutics Limited, H2 2016 36

Diabetic Retinopathy – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 37

Diabetic Retinopathy – Pipeline by BCN Peptides, S.A., H2 2016 38

Diabetic Retinopathy – Pipeline by Biomar Microbial Technologies, H2 2016 39

Diabetic Retinopathy – Pipeline by Charlesson LLC., H2 2016 40

Diabetic Retinopathy – Pipeline by Coherus BioSciences, Inc., H2 2016 41

Diabetic Retinopathy – Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 42

Diabetic Retinopathy – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 43

Diabetic Retinopathy – Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 44

Diabetic Retinopathy – Pipeline by Dynamis Therapeutics, Inc., H2 2016 45

Diabetic Retinopathy – Pipeline by EyeGene Inc, H2 2016 46

Diabetic Retinopathy – Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 47

Diabetic Retinopathy – Pipeline by Formycon AG, H2 2016 48

Diabetic Retinopathy – Pipeline by Icon Bioscience, Inc., H2 2016 49

Diabetic Retinopathy – Pipeline by Islet Sciences, Inc., H2 2016 50

Diabetic Retinopathy – Pipeline by Kodiak Sciences Inc., H2 2016 51

Diabetic Retinopathy – Pipeline by Kowa Company, Ltd., H2 2016 52

Diabetic Retinopathy – Pipeline by LegoChem Biosciences, Inc, H2 2016 53

Diabetic Retinopathy – Pipeline by Lpath, Inc., H2 2016 54

Diabetic Retinopathy – Pipeline by M's Science Corporation, H2 2016 55

Diabetic Retinopathy – Pipeline by Mabion SA, H2 2016 56

Diabetic Retinopathy – Pipeline by MingSight Pharmaceuticals, H2 2016 57

Diabetic Retinopathy – Pipeline by OcuCure Therapeutics, Inc., H2 2016 58

Diabetic Retinopathy – Pipeline by Oculis ehf, H2 2016 59

Diabetic Retinopathy – Pipeline by Ohr Pharmaceutical Inc., H2 2016 60

Diabetic Retinopathy – Pipeline by PanOptica, Inc., H2 2016 61

Diabetic Retinopathy – Pipeline by Profarma, H2 2016 62

Diabetic Retinopathy – Pipeline by Promedior, Inc., H2 2016 63

Diabetic Retinopathy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 64

Diabetic Retinopathy – Pipeline by Retrotope, Inc, H2 2016 65

Diabetic Retinopathy – Pipeline by Ribomic Inc., H2 2016 66

Diabetic Retinopathy – Pipeline by Stelic Institute & Co., Inc., H2 2016 67

Diabetic Retinopathy – Pipeline by Stemedica Cell Technologies, Inc., H2 2016 68

Diabetic Retinopathy – Pipeline by Strongbridge Biopharma plc , H2 2016 69

Diabetic Retinopathy – Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 70

Diabetic Retinopathy – Pipeline by Targazyme, Inc., H2 2016 71

Diabetic Retinopathy – Pipeline by ThromboGenics NV, H2 2016 72

Diabetic Retinopathy – Pipeline by TWi Pharmaceuticals, Inc., H2 2016 73

Diabetic Retinopathy – Pipeline by VESSL Therapeutics Ltd, H2 2016 74

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Stage and Target, H2 2016 78

Number of Products by Stage and Mechanism of Action, H2 2016 82

Number of Products by Stage and Route of Administration, H2 2016 86

Number of Products by Stage and Molecule Type, H2 2016 88

Diabetic Retinopathy – Dormant Projects, H2 2016 217

Diabetic Retinopathy – Dormant Projects (Contd..1), H2 2016 218

Diabetic Retinopathy – Dormant Projects (Contd..2), H2 2016 219

Diabetic Retinopathy – Dormant Projects (Contd..3), H2 2016 220

Diabetic Retinopathy – Dormant Projects (Contd..4), H2 2016 221

Diabetic Retinopathy – Dormant Projects (Contd..5), H2 2016 222

Diabetic Retinopathy – Discontinued Products, H2 2016 223

List of Figures

List of Figures

Number of Products under Development for Diabetic Retinopathy, H2 2016 16

Number of Products under Development for Diabetic Retinopathy – Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 75

Number of Products by Top 10 Targets, H2 2016 77

Number of Products by Stage and Top 10 Targets, H2 2016 77

Number of Products by Top 10 Mechanism of Actions, H2 2016 81

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 81

Number of Products by Top 10 Routes of Administration, H2 2016 85

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 85

Number of Products by Top 10 Molecule Types, H2 2016 87

Number of Products by Stage and Top 10 Molecule Types, H2 2016 87

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports